|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Veronesi U, Boyle P, Goldhirsch A, et al:
Breast cancer. Lancet. 365:1727–1741. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bartkova J, Lukas J, Strauss M and Bartek
J: Cyclin D1 onco-protein aberrantly accumulates in malignancies of
diverse histogenesis. Oncogene. 10:775–778. 1995.PubMed/NCBI
|
|
5.
|
Porter-Jordan K and Lippman ME: Overview
of the biologic markers of breast cancer. Hematol Oncol Clin North
Am. 8:73–100. 1994.PubMed/NCBI
|
|
6.
|
Callahan R, Cropp CS, Merlo GR, et al:
Somatic mutations and human breast cancer. A status report Cancer.
69(Suppl): 1582–1588. 1992.PubMed/NCBI
|
|
7.
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Li Z, Ni M, Li J, Zhang Y, Ouyang Q and
Tang C: Decision making of the p53 network: Death by integration. J
Theor Biol. Dec 3–2010.(Epub ahead of print).
|
|
9.
|
Brosh R and Rotter V: When mutants gain
new powers: news from the mutant p53 field. Nat Rev Cancer.
9:701–713. 2009.PubMed/NCBI
|
|
10.
|
Bennett WP, Hussain SP, Vahakangas KH,
Khan MA, Shields PG and Harris CC: Molecular epidemiology of human
cancer risk: gene-environment interactions and p53 mutation
spectrum in human lung cancer. J Pathol. 187:8–18. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ravi R, Mookerjee B, Bhujwalla ZM, et al:
Regulation of tumor angiogenesis by p53-induced degradation of
hypoxia-inducible factor 1alpha. Genes Dev. 14:34–44.
2000.PubMed/NCBI
|
|
12.
|
Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC and
Yang PC: Aberrant p53 expression correlates with expression of
vascular endothelial growth factor mRNA and interleukin-8 mRNA and
neoangiogenesis in non-small-cell lung cancer. J Clin Oncol.
20:900–910. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Mhawech P, Kinkel K, Vlastos G and Pelte
MF: Ovarian carcinomas in endometriosis: an immunohistochemical and
comparative genomic hybridization study. Int J Gynecol Pathol.
21:401–406. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Zhou Y, Li N, Zhuang W, et al: P53 codon
72 polymorphism and gastric cancer: a meta-analysis of the
literature. Int J Cancer. 121:1481–1486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Harris N, Brill E, Shohat O, et al:
Molecular basis for heterogeneity of the human p53 protein. Mol
Cell Biol. 6:4650–4656. 1986.PubMed/NCBI
|
|
16.
|
Dumont P, Leu JI, Della Pietra AC III, et
al: The codon 72 polymorphic variants of p53 have markedly
different apoptotic potential. Nat Genet. 33:357–365. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
|
|
18.
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Zhang Z, Wang M, Wu D, Wang M, Tong N,
Tian Y and Zhang Z: P53 codon 72 polymorphism contributes to breast
cancer risk: a meta-analysis based on 39 case-control studies.
Breast Cancer Res Treat. 120:509–517. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Damin AP, Frazzon AP, Damin DC, et al:
Evidence for an association of TP53 codon 72 polymorphism with
breast cancer risk. Cancer Detect Prev. 30:523–529. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Själander A, Birgander R, Hallmans G, et
al: p53 polymorphisms and haplotypes in breast cancer.
Carcinogenesis. 17:1313–1316. 1996.
|
|
23.
|
Kalemi TG, Lambropoulos AF, Gueorguiev M,
Chrisafi S, Papazisis KT and Kotsis A: The association of p53
mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T
polymorphisms with breast cancer in Northern Greece. Cancer Lett.
222:57–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Akkiprik M, Sonmez O, Gulluoglu BM, Caglar
HB, Kaya H, Demirkalem P, Abacioglu U, Sengoz M, Sav A and Ozer A:
Analysis of p53 gene polymorphisms and protein over-expression in
patients with breast cancer. Pathol Oncol Res. 15:359–368. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Buyru N, Tigli H and Dalay N: P53 codon 72
polymorphism in breast cancer. Oncol Rep. 10:711–714. 2003.
|
|
26.
|
Gochhait S, Bukhari SI, Bairwa N, et al:
Implication of BRCA2-26G>A 5′ untranslated region polymorphism
in susceptibility to sporadic breast cancer and its modulation by
p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res.
9:R712007.PubMed/NCBI
|
|
27.
|
Henríquez-Hernández LA, Murias-Rosales A,
Hernández González A, et al: Gene polymorphisms in TYMS, MTHFR, p53
and MDR1 as risk factors for breast cancer: A case-control study.
Oncol Rep. 22:1425–1433. 2009.PubMed/NCBI
|
|
28.
|
Huang XE, Hamajima N, Katsuda N, Matsuo K,
Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S and
Tajima K: Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14
at exon 2 genetic polymorphisms with the risk of Japanese breast
cancer. Breast Cancer Res. 10:307–311. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Katiyar S, Thelma BK, Murthy NS, Hedau S,
Jain N, Gopalkrishna V, Husain SA and Das BC: Polymorphism of the
p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated
cervical and oral cancer in India. Mol Cell Biochem. 252:117–124.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Li T, Lu ZM, Guo M, Wu QJ, Chen KN, Xing
HP, Mei Q and Ke Y: p53 codon 72 polymorphism (C/G) and the risk of
human papillomavirus-associated carcinomas in China. Cancer.
95:2571–2576. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Sprague BL, Trentham-Dietz A,
Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock
SJ, Haines JL and Egan KM: Genetic variation in TP53 and risk of
breast cancer in a population-based case control study.
Carcinogenesis. 28:1680–1686. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Wang-Gohrke S, Becher H, Kreienberg R,
Runnebaum IB and Chang-Claude J: Intron 3 16 bp duplication
polymorphism of p53 is associated with an increased risk for breast
cancer by the age of 50 years. Pharmacogenetics. 12:269–272.
2002.PubMed/NCBI
|
|
33.
|
Weston A and Godbold JH: Polymorphisms of
H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis.
Environ Health Perspect. 105(Suppl 4): 919–926. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Zhang W, Jin MJ and Chen K: Association of
p53 polymor-phisms and its haplotypes with susceptibility of breast
cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban. 36:561–566. 2007.(In
Chinese).
|
|
35.
|
Baynes C, Healey CS, Pooley KA, Scollen S,
et al SEARCH breast cancer study: Common variants in the ATM,
BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are
unlikely to increase breast cancer risk. Breast Cancer Res.
9:R272007. View
Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Mabrouk I, Baccouche S, El-Abed R,
Mokdad-Gargouri R, Mosbah A, Saïd S, Daoud J, Frikha M, Jlidi R and
Gargouri A: No evidence of correlation between p53 codon 72
polymorphism and risk of bladder or breast carcinoma in Tunisian
patients. Ann NY Acad Sci. 1010:764–770. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Khadang B, Fattahi MJ, Talei A, Dehaghani
AS and Ghaderi A: Polymorphism of TP53 codon 72 showed no
association with breast cancer in Iranian women. Cancer Genet
Cytogenet. 173:38–42. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Schmidt MK, Reincke S, Broeks A, et al: Do
MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility?
A large pooled series from the breast cancer association
consortium. Cancer Res. 67:9584–9590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Tommiska J, Eerola H, Heinonen M, Salonen
L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K,
Heikkilä P, Blomqvist C and Nevanlinna H: Breast cancer patients
with p53 Pro72 homozygous genotype have a poorer survival. Clin
Cancer Res. 11:5098–5103. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Kawajiri K, Nakachi K, Imai K, Watanabe J
and Hayashi S: Germ line polymorphisms of p53 and CYP1A1 genes
involved in human lung cancer. Carcinogenesis. 14:1085–1089. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Khaliq S, Hameed A, Khaliq T, et al: P53
mutations, polymorphisms, and haplotypes in Pakistani ethnic groups
and breast cancer patients. Genet Test. 4:23–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Mahasneh AA and Abdel-Hafiz SS:
Polymorphism of p53 gene in Jordanian population and possible
associations with breast cancer and lung adenocarcinoma. Saudi Med
J. 25:1568–1573. 2004.PubMed/NCBI
|
|
43.
|
Noma C, Miyoshi Y, Taguchi T, Tamaki Y and
Noguchi S: Association of p53 genetic polymorphism (Arg72Pro) with
estrogen receptor positive breast cancer risk in Japanese women.
Cancer Lett. 210:197–203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Siddique MM, Balram C, Fiszer-Maliszewska
L, Aggarwal A, Tan A, Tan P, Soo KC and Sabapathy K: Evidence for
selective expression of the p53 codon 72 polymorphs: implications
in cancer development. Cancer Epidemiol Biomarkers Prev.
14:2245–2252. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J,
Chen W, Jin G, Liu J, Gao J, Wang X, Wei Q and Shen H: Joint
effects of single nucleotide polymorphisms in P53BP1 and p53 on
breast cancer risk in a Chinese population. Carcinogenesis.
27:766–771. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Rajkumar T, Samson M, Rama R, Sridevi V,
Mahji U, Swaminathan R and Nancy NK: TGFβ1 (Leu10Pro), p53
(Arg72Pro) can predict for increased risk for breast cancer in
south Indian women and TGFβ1 Pro (Leu10Pro) allele predicts
response to neo-adjuvant chemo radiotherapy. Breast Cancer Res
Treat. 112:81–87. 2008.
|
|
47.
|
Lum SS, Chua HW, Li H, Li WF, Rao N, Wei
J, Shao Z and Sabapathy K: MDM2 SNP309 G allele increases risk but
the T allele is associated with earlier onset age of sporadic
breast cancers in the Chinese population. Carcinogenesis.
29:754–761. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Singh V, Rastogi N, Mathur N, Singh K and
Singh MP: Association of polymorphism in MDM-2 and p53 genes with
breast cancer risk in Indian women. Ann Epidemiol. 18:48–57. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Kazemi M, Salehi Z and Chakosari RJ: TP53
codon 72 polymorphism and breast cancer in northern Iran. Oncol
Res. 18:25–30. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Song F, Zheng H, Liu B, Wei S, Dai H,
Zhang L, Calin GA, Hao X, Wei Q, Zhang W and Chen K: An
miR-502-binding site single-nucleotide polymorphism in the
3′-untranslated region of the SET8 gene is associated with early
age of breast cancer onset. Clin Cancer Res. 15:6292–6300.
2009.
|
|
51.
|
Koh WP, Van Den Berg D, Jin A, Wang R,
Yuan JM and Yu MC: Combined effects of MDM2 SNP309 and TP53 R72P
polymorphisms, and soy isoflavones on breast cancer risk among
Chinese women in Singapore. Breast Cancer Res Treat. 130:1011–1019.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Kara N, Karakus N, Ulusoy AN, Ozaslan C,
Gungor B and Bagci H: P53 codon 72 and HER2 codon 655 polymorphisms
in Turkish breast cancer patients. DNA Cell Biol. 29:387–392. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC
and Lee YJ: Involvement of p53 R72P polymorphism in the association
of MDM2-SNP309 with breast cancer. Oncol Rep. 25:1755–1763.
2011.PubMed/NCBI
|
|
54.
|
Wang-Gohrke S, Rebbeck TR, Besenfelder W,
et al: p53 germline polymorphisms are associated with an increased
risk for breast cancer in German women. Anticancer Res.
18:2095–2099. 1998.PubMed/NCBI
|
|
55.
|
Papadakis EN, Dokianakis DN and Spandidos
DA: p53 codon 72 polymorphism as a risk factor in the development
of breast cancer. Mol Cell Biol Res Commun. 3:389–392. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Suspitsin EN, Buslov KG, Grigoriev MY, et
al: Evidence against involvement of p53 polymorphism in breast
cancer predisposition. Int J Cancer. 103:431–433. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Menzel HJ, Sarmanova J, Soucek P,
Berberich R, Grünewald K, Haun M and Kraft HG: Association of NQO1
polymorphism with spontaneous breast cancer in two independent
populations. Br J Cancer. 90:1989–1994. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Ohayon T, Gershoni-Baruch R, Papa MZ,
Distelman Menachem T, Eisenberg Barzilai S and Friedman E: The R72P
P53 mutation is associated with familial breast cancer in Jewish
women. Br J Cancer. 92:1144–1148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Garcia-Closas M, Kristensen V, Langerød A,
et al: Common genetic variation in TP53 and its flanking genes,
WDR79 and ATP1B2, and susceptibility to breast cancer. Int J
Cancer. 121:2532–2538. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Franeková M, Zúbor P, Stanclová A, Dussan
CA, Bohusová T, Galo S, Dobrota D, Kajo K, Péc M and Racay P:
Association of p53 polymorphisms with breast cancer: a case-control
study in Slovak population. Neoplasma. 54:155–161. 2007.PubMed/NCBI
|
|
61.
|
Johnson N, Fletcher O, Palles C, et al:
Counting potentially functional variants in BRCA1, BRCA2 and ATM
predicts breast cancer susceptibility. Hum Mol Genet. 16:1051–1057.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Cavallone L, Arcand SL, Maugard C,
Ghadirian P, Mes-Masson AM, Provencher D and Tonin PN: Haplotype
analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and
BRCA2 mutation carriers of French Canadian descent. BMC Cancer.
8:962008. View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Costa S, Pinto D, Pereira D, Rodrigues H,
Cameselle-Teijeiro J, Medeiros R and Schmitt F: Importance of TP53
codon 72 and intron 3 duplication 16 bp polymorphisms in prediction
of susceptibility on breast cancer. BMC Cancer. 8:322008.
View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
De Vecchi G, Verderio P, Pizzamiglio S, et
al: The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes
are not associated with breast cancer risk in BRCA-mutation
negative familial cases. Cancer Detect Prev. 32:140–143.
2008.PubMed/NCBI
|
|
65.
|
Nordgard SH, Alnaes GI, Hihn B, et al:
Pathway based analysis of SNPs with relevance to 5-FU therapy:
relation to intratumoral mRNA expression and survival. Int J
Cancer. 123:577–585. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Lång A, Palmebäck Wegman P and Wingren S:
The significance of MDM2 SNP309 and p53 Arg72Pro in young women
with breast cancer. Oncol Rep. 22:575–579. 2009.PubMed/NCBI
|
|
67.
|
Aoki MN, da Silva do Amaral Herrera AC,
Amarante MK, do Val Carneiro JL, Fungaro MH and Watanabe MA: CCR5
and p53 codon 72 gene polymorphisms: implications in breast cancer
development. Int J Mol Med. 23:429–435. 2009.PubMed/NCBI
|
|
68.
|
Hrstka R, Beranek M, Klocova K, Nenutil R
and Vojtesek B: Intronic polymorphisms in TP53 indicate lymph node
metastasis in breast cancer. Oncol Rep. 22:1205–1211.
2009.PubMed/NCBI
|
|
69.
|
Bisof V, Salihović MP, Narancić NS,
Skarić-Jurić T, Jakić-Razumović J, Janićijević B, Turek S and Rudan
P: TP53 gene polymorphisms and breast cancer in Croatian women: a
pilot study. Eur J Gynaecol Oncol. 31:539–544. 2010.PubMed/NCBI
|
|
70.
|
Ebner F, Schremmer-Danninger E and Rehbock
J: The role of TP53 and p21 gene polymorphisms in breast cancer
biology in a well specified and characterized German cohort. J
Cancer Res Clin Oncol. 136:1369–1375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71.
|
Alshatwi AA, Hasan TN, Shafi G, Alsaif MA,
Al-Hazzani AA and Alsaif AA: A single-nucleotide polymorphism in
the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic
Arab population. Fundam Clin Pharmacol. 26:438–443. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Alawadi S, Ghabreau L, Alsaleh M,
Abdulaziz Z, Rafeek M, Akil N and Alkhalaf M: P53 gene
polymorphisms and breast cancer risk in Arab women. Med Oncol.
28:709–715. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Weston A, Ling-Cawley HM, Caporaso NE, et
al: Determination of the allelic frequencies of an L-myc and a p53
polymorphism in human lung cancer. Carcinogenesis. 15:583–587.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Helland A, Langerød A, Johnsen H, Olsen
AO, Skovlund E and Børresen-Dale AL: p53 polymorphism and risk of
cervical cancer. Nature. 396:530–531. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
75.
|
Cox DG, Deer D, Guo Q, Tworoger SS,
Hankinson SE, Hunter DJ and De Vivo I: The p53 Arg72Pro and
MDM2-309 polymorphisms and risk of breast cancer in the nurses’
health studies. Cancer Causes Control. 18:621–625. 2007.PubMed/NCBI
|
|
76.
|
Gaudet MM, Gammon MD, Bensen JT, Sagiv SK,
Shantakumar S, Teitelbaum SL, Eng SM, Neugut AI and Santella RM:
Genetic variation of TP53, polycyclic aromatic hydrocarbon-related
exposures, and breast cancer risk among women on Long Island, New
York. Breast Cancer Res Treat. 108:93–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
77.
|
Denisov EV, Cherdyntseva NV, Litvyakov NV,
et al: TP53 mutations and Arg72Pro polymorphism in breast cancers.
Cancer Genet Cytogenet. 192:93–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
